Abstract 5227
Background
There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC.
Methods
The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study.
Results
Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P<.001). Also, the latter group of pts had worse OS than the first group ( median 103 vs 153 mths, P=.030). Median DFS for pts had MRM was significantly better than patients had limited surgery (one-third of those pts had no axillary dissection)(118 vs 57 mths, P=.002). Two HER2-positive pts treated with adjuvant trastuzumab containing regimen had breast cancer recurrence(n = 11) and alive whereas 9 of 19 pts treated other chemotherapy regimen (All but 2 anthracycline and/or taxane based) had experienced the disease relapse and 7 of them died from MBC.
Conclusions
Although the adjuvant use of anthracyclines /taxanes and trastuzumab for MBC have increased in the last 10 years, stage at diagnosis is still important prognostic factor for survival in MBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4874 - Complete Responses in Patients With 2nd-Line or Greater Metastatic Triple-Negative Breast Cancer (TNBC) Following First-in-Human Immunotherapy Combining NK and T Cell Activation with Off-the-Shelf High-Affinity CD16 NK Cell Line (haNK)
Presenter: Chaitali Nangia
Session: Poster Display session 2
Resources:
Abstract
4362 - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)
Presenter: Aurelia Noske
Session: Poster Display session 2
Resources:
Abstract
4528 - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy
Presenter: Peter Kaufman
Session: Poster Display session 2
Resources:
Abstract
4112 - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Presenter: Yang Chen
Session: Poster Display session 2
Resources:
Abstract
5699 - Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Joyce O’Shaughnessy
Session: Poster Display session 2
Resources:
Abstract
1931 - Maintenance Chemotherapy is effective in Patients with Metastatic Triple Negative Breast Cancer After First-line Platinum-based Chemotherapy
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
4696 - Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to investigate symptom burden enrichment in Stage IV patients at an academic center
Presenter: Madeline Matthys
Session: Poster Display session 2
Resources:
Abstract
4582 - Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS
Presenter: Meghan Karuturi
Session: Poster Display session 2
Resources:
Abstract
3565 - Real-World 1-Year Survival Analysis of Patients with Metastatic Breast Cancer with Liver or Lung Metastasis Treated with Eribulin, Gemcitabine or Capecitabine
Presenter: Shayma Kazmi
Session: Poster Display session 2
Resources:
Abstract
3608 - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer
Presenter: Khalil SALEH
Session: Poster Display session 2
Resources:
Abstract